Clinical Scorecard: Utilizing rituximab in the conditioning phase may reduce the risk of Epstein-Barr virus infection after rATG-based haploidentical hematopoietic stem cell transplantation during letermovir use for cytomegalovirus prophylaxis

At a Glance

Key Highlights

• Rituximab reduced EBV viremia incidence from 22.67% to 4.00% in one year post-transplantation.
• Lower incidence of acute graft-versus-host disease (aGVHD) in rituximab group (28% vs. 50.67%).
• No significant differences in CMV viremia and chronic GVHD between groups.
• 2-year overall survival rates were similar between rituximab and control groups.
• Prospective randomized controlled trials are needed for further validation.

Guideline-Based Recommendations

Diagnosis

• Monitor EBV-DNA levels post-transplantation.

Management

• Consider rituximab in conditioning regimens for haplo-HSCT to prevent EBV reactivation.

Monitoring & Follow-up

• Regularly assess for EBV viremia and PTLD in post-transplant patients.

Risks

• Potential for acute and chronic graft-versus-host disease.

Patient & Prescribing Data

Patients aged 18 and older undergoing first haplo-HSCT with rATG for GVHD prophylaxis.

Rituximab (375 mg/m²) administered on day -3 before transplantation.

Clinical Best Practices

• Implement EBV monitoring protocols in post-transplant care.
• Utilize a combination of immunosuppressive therapies for GVHD prophylaxis.

Related Resources & Content

• Study on EBV reactivation post-transplantation